50 Under 50 Nominations Are Open!

Nominations close November 6th at 11:59PM EST.

#538 - Why did two clinical AI founders bet on the paperwork instead? | Shaju Puthussery (CEO, Lightspun) & Deepak Ramaswamy (CTO)

#537 - Is the smart home finally becoming healthcare infrastructure? | Mike McSherry (CEO, Xealth)

Market Take: Boston Life Sciences Real Estate Shows Improving Momentum

Greater Boston’s lab and life sciences property market is still working through elevated vacancy and oversupply, but major tenant commitments, stronger funding activity, and new manufacturing investment are pointing toward a gradual recovery.

"340B is going away." People have said that for 30 years. VytlOne's CEO explains why they keep being wrong.

Kim Tzoumakas came to pharmacy after two decades as a healthcare lawyer. Her core argument: 340B isn't a loophole or a relic. It's infrastructure. Here's how that belief shapes the way she builds product, runs a CFO conversation, and draws the line on AI.

#536 - Is 340B really going away — or finally becoming infrastructure? | Kim Tzoumakas (CEO, VytlOne)

One drug. Five specialties. Nobody coordinating.

How GLP-1s broke the point-solution model, and why coordination is becoming the moat. With Mark Clermont and Wendi Mader of Cecelia Health.

#535 - Why is chronic disease still winning? | Mark Clermont (CEO, Cecelia Health) & Wendi Mader (CCO)

A decade of "fixing" healthcare. Here's what everyone missed.

Cotiviti's new CEO thinks the whole industry has been misdiagnosing the trillion-dollar problem.